NCT06760455View on ClinicalTrials.gov

A Safety and Tolerability Study of BPR-30221616 Injection in Healthy Subjects

PHASE1RecruitingINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

January 10, 2025

Primary Completion Date

January 24, 2026

Study Completion Date

December 5, 2026

Conditions
Healthy Participants
Interventions
DRUG

BPR-30221616 Injection

BPR-30221616 will be administered by subcutaneous (SC) injection

DRUG

Sodium Chloride Injection

Sodium Chloride Injection will be administered by SC injection

Trial Locations (1)

100730

RECRUITING

Peking Union Medical College Hospital, Beijing

All Listed Sponsors
lead

Chengdu Brilliant Pharmaceutical Co., Ltd.

INDUSTRY